Albuterol News
Drugs
> AlbuterolAlbuterol News is an EIN News Service for health professionals. Constantly updated news and information about health.
- Indacaterol Produces Effective Bronchodilation in Patients With COPD During 1 Year of Treatment: Presented at CHEST 2009 7 Nov 2009 07:55 GMT
... Patients With COPD During 1 Year of Treatment: Presented at CHEST 2009 SAN DIEGO -- ... and Critical Care Section, University of Nebraska Medical Center, Omaha, Nebraska, and colleagues reported their ... (SGRQ), exacerbations of COPD, and use of albuterol as a rescue medication. Patients with moderate ...
- MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease 3 Nov 2009 23:31 GMT
... evaluate the safety of MN-221 for the treatment of COPD exacerbations will involve approximately 48 ... bypasses the constricted airways to deliver the drug to the lungs. In addition to the ... by intravenous administration in combination with inhaled albuterol does not add to the heart rate ...
- MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Mod 3 Nov 2009 23:35 GMT
... evaluate the safety of MN-221 for the treatment of COPD exacerbations will involve approximately 48 ... bypasses the constricted airways to deliver the drug to the lungs. In addition to the ... by intravenous administration in combination with inhaled albuterol does not add to the heart rate ...
- MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chr 3 Nov 2009 23:52 GMT
... evaluate the safety of MN-221 for the treatment of COPD exacerbations will involve approximately 48 ... bypasses the constricted airways to deliver the drug to the lungs. In addition to the ... by intravenous administration in combination with inhaled albuterol does not add to the heart rate ...
- MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (GNW) 3 Nov 2009 23:35 GMT
... evaluate the safety of MN-221 for the treatment of COPD exacerbations will involve approximately 48 ... bypasses the constricted airways to deliver the drug to the lungs. In addition to the ... by intravenous administration in combination with inhaled albuterol does not add to the heart rate ...
- Teva Reports Third Quarter 2009 Results 3 Nov 2009 07:00 GMT
... as the world's leading therapy for the treatment of multiple sclerosis, and of ProAir(TM), the leading Albuterol inhaler in the U.S." Mr. Yanai continued: ... the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory ...
- Novel LABA Improves Lung Function in COPD 5 Nov 2009 17:02 GMT
... researchers reported here. Through 26 weeks, the drug significantly improved bronchodilation, health status, and dyspnea ... randomized, double-blind, placebo-controlled trial that compared once-daily treatment with 150 mcg of indacaterol, twice-daily treatment ... mean age of the patients was 63.5. Post-albuterol FEV was 53.4% of the predicted value, ...
- Teva beats estimates as Copaxone sales hit record 3 Nov 2009 07:35 GMT
... of 2008. In-market sales of Teva's MS drug Copaxone reached a record $776 million, up ... market share of approximately 30% in MS treatments. In the US, in-market sales increased 53% ... multiple sclerosis, and of ProAir, the leading Albuterol inhaler in the U.S. "This is the ...
- Teva misses revenue estimates as Copaxone sales hit record 3 Nov 2009 08:15 GMT
... of 2008. In-market sales of Teva's MS drug Copaxone reached a record $776 million, up ... market share of approximately 30% in MS treatments. In the US, in-market sales increased 53% ... multiple sclerosis, and of ProAir, the leading Albuterol inhaler in the U.S. "This is the ...
- Teva Reports Third Quarter 2009 Results (BIZ) 3 Nov 2009 07:00 GMT
... as the world's leading therapy for the treatment of multiple sclerosis, and of ProAir , the leading Albuterol inhaler in the U.S." Mr. Yanai continued: ... compared with the third quarter last year. Pharmaceutical sales in North America for the third ...
- Teva misses revenue estimates 3 Nov 2009 09:35 GMT
... of 2008. In-market sales of Teva's MS drug Copaxone reached a record $776 million, up ... market share of approximately 30% in MS treatments. In the US, in-market sales increased 53% ... multiple sclerosis, and of ProAir, the leading Albuterol inhaler in the U.S. "This is the ...
- New asthma research presented at CHEST 2009 4 Nov 2009 00:52 GMT
... from five US institutions, including Rush University Medical Center in Illinois and Johns Hopkins Medical ... using local anesthesia at the insertion site. Treatment consisted of up to 180 minutes of ... the length of hospital stay. High-Dose Inhaled Albuterol Associated With Metabolic Acidosis (#8423, Tuesday, November ...
- Teva 3rd-quarter Net Up 2.9%, Sales Up 25% 3 Nov 2009 08:12 GMT
... as the world's leading therapy for the treatment of multiple sclerosis, and of ProAir, the leading Albuterol inhaler in the U.S." Mr. Yanai continued: ... we have higher expenses than sales," Teva Pharmaceutical reports. Non-GAAP net income for the third ...
- New pediatric lung health research presented at CHEST 2009 4 Nov 2009 00:52 GMT
... the length of hospital stay. High-Dose Inhaled Albuterol Associated With Metabolic Acidosis (#8423, Tuesday, November ... retrospective analysis, researchers from Yale School of Medicine reviewed demographic and physiologic data of 201 ...
- Presented At CHEST 2009 - New Pediatric Lung Health Research 4 Nov 2009 11:30 GMT
... the length of hospital stay. High-Dose Inhaled Albuterol Associated With Metabolic Acidosis (#8423) Patients with ... retrospective analysis, researchers from Yale School of Medicine reviewed demographic and physiologic data of 201 ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
bbc.co.uk:
healthday.com:
reuters.com: